Novartis: Scemblix approved in the EU for adults with chronic myeloid leukemia

[August 29, 2022]  ZURICH (Reuters) - Novartis said on Monday its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies.

Patients with CML generally receive oral tyrosine kinase inhibitor therapies, and those experiencing side effects or resistance have little hope of controlling their disease, the Swiss pharma group said in a statement.

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann

Scemblix relies on a novel mechanism, acting as a STAMP inhibitor, Novartis said.

(Reporting by Silke Koltrowitz; Editing by Paul Carrel)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.